We studied the association of polymorphic markers of cell cycle control genes (Arg72Pro of the TP53 gene, T(-410)G of the MDM2 gene, and Ser31Arg of the CDKN1A gene) in ovarian cancer and progression-free survival following platinum-based chemotherapy. Tumor tissue samples obtained from 49 patients who had undergone chemotherapy were examined. Patients received standard platinum-based chemotherapy and were observed until disease progression. Polymorphic markers of genes were evaluated by PCR-RFLP and real-time PCR. In patients carrying the G allele of the T(-410)G marker of the MDM2 gene, a decreasing trend was observed in median progression-free survival. An increase in the median progression-free survival was observed in carriers of the Pro allele of the TP53 gene (p=0.045). Furthermore, a stronger association was noted with carriers of the minor Pro/Pro homozygous genotype relative to the Arg/Arg genotype (p=0.007). In the subgroup of patients who underwent optimal or complete cytoreductive surgery, carriage of the minor Arg allele of the Ser31Arg marker (CDN1A gene) was associated with a decrease in the median progression-free survival time (p=0.004).

中文翻译：

---

TP53、MDM2和CDKN1A基因的分子遗传标志物与卵巢癌患者铂类化疗后无进展生存的关联

我们研究了细胞周期控制基因的多态性标志物（TP53 基因的 Arg72Pro、MDM2 基因的 T(-410)G 和 CDKN1A 基因的 Ser31Arg）与铂类化疗后无进展生存期的关联. 检查了从接受化疗的 49 名患者获得的肿瘤组织样本。患者接受标准的铂类化疗并观察直至疾病进展。通过PCR-RFLP和实时PCR评估基因的多态性标记。在携带 MDM2 基因 T(-410)G 标记的 G 等位基因的患者中，观察到中位无进展生存期呈下降趋势。在 TP53 基因的 Pro 等位基因携带者中观察到中位无进展生存期增加 (p=0.045)。此外，注意到与相对于 Arg/Arg 基因型的次要 Pro/Pro 纯合基因型的携带者有更强的关联 (p=0.007)。在接受最佳或完全减瘤手术的患者亚组中，携带 Ser31Arg 标志物（CDN1A 基因）的次要 Arg 等位基因与中位无进展生存时间的减少相关（p = 0.004）。